Nathan M. Radcliffe, MD, is a board-certified Ophthalmologist specializing in Glaucoma and Cataract Surgery.
Dr. Radcliffe graduated Alpha Omega Alpha from Temple University School of Medicine. He continued his education as an intern at University of Hawaii in Honolulu, where he was awarded “Transitional Resident of the Year”. Dr. Radcliffe served as the Chief Resident at New York University during his ophthalmology residency and was the Chief Glaucoma Fellow at the New York Eye and Ear Infirmary.
In September of 2017, Dr. Radcliffe joined the advanced Microincisional Glaucoma Surgery Center at New York Eye and Ear Infirmary. Prior to this appointment, Dr. Radcliffe most recently served as the Section Director of Glaucoma services at NYU and Bellevue hospital and previously the Section Director of Glaucoma division at Weill Cornell Medical Center. Dr. Radcliffe splits his time between NEEI and the New York Eye Surgery Center in the Bronx, where he manages some of the most challenging cataract and glaucoma cases.
Dr. Radcliffe is regarded as a leader in the field of Glaucoma, more specifically in the innovations of minimally invasive, “microincisional”, glaucoma surgery. He has been recognized as a rising star, and was recognized as a “Top 40 Ophthalmologist Under 40” by The Ophthalmologist journal. Dr. Radcliffe has published over 40 peer-reviewed publications in glaucoma research. He is committed to teaching others, from residents to experienced surgeons alike, and has given hundreds of lectures to thousands of ophthalmologists in 40 states and over a dozen different countries. He has won awards for his surgical videos and teaching, including the NYU Residents Teaching Award in 2015.
Dr. Radcliffe practices at the highest level, blending academic science to elevate private practice clinical medicine. He is a microincisional glaucoma surgery (MIGS) innovator and instructor. At New York Eye Surgery Center, he was the first surgeon in New York to offer patients the CyPass supraciliary microstent, the Kahook Dual Blade Goniotomy, Visco360 and Trab360, the G6 micropulse laser, and Allergan’s Xen subconjunctival implant. Dr. Radcliffe was the second New York surgeon in 2012 to offer the Glaukos iStent. He continues to perform many microstents and MIGS surgeries each week, and teaches other glaucoma specialists these techniques locally in NY, and on the national stage at the annual American Academy of Ophthalmology (AAO) and American Society of Cataract and Refractive Surgery (ASCRS) meetings.
Dr. Radcliffe was involved in the development of a minimally invasive glaucoma laser therapy, known as “micropulse laser cyclophotocoagulation”, and performs more Ahmed Valve surgeries each year than any American glaucoma surgeon. This vast experience gives Dr. Radcliffe the very unique ability to customize the most appropriate therapies, both medical and surgical, to the Glaucoma patients that he serves, as he performs every FDA-approved traditional and MIGS glaucoma procedures in the US.